Vaccine access reports

In Australia, our vaccines have been at the heart of the NIP from the time it began, helping to protect infants and children from multiple serious diseases. Beyond childhood, our vaccines help protect Australians throughout life, whether at home, or travelling overseas. GSK has commissioned three reports examining the opportunity to boost access to vaccination for Australian adults.

Our vaccine access reports

diverse mix of adults office setting 30-40yrs

Prevention: a productivity superpower

An assessment of the economic value of vaccines. It demonstrates the value of vaccines in boosting productivity while reducing a range of government and social costs: across health, tax, aged care, disability and carer support.

Prevention: a productivity superpower

Risk to resilience: a roadmap to vaccine access for older Australians

An exploration of the potential to strengthen Australia's NIP to benefit more people. It quantifies the benefits of an NIP that draws on its previous success by expanding its focus to include providing the latest advances in vaccines for older Australians.

Risk to resilience: a roadmap to vaccine access for older Australians

The value of vaccines

Ensuring Australia keeps pace with community values and best practice. This was a policy paper identifying areas in the current process that could be updated to better align with international best practice and community values.

The value of vaccines